Valneva (NASDAQ:VALN) Trading Down 3.6% - Time to Sell?

Valneva SE (NASDAQ:VALN - Get Free Report)'s stock price traded down 3.6% during trading on Tuesday . The company traded as low as $6.25 and last traded at $6.34. 13,562 shares traded hands during mid-day trading, a decline of 81% from the average session volume of 71,096 shares. The stock had previously closed at $6.57.

Analysts Set New Price Targets

VALN has been the subject of several recent analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $17.00 price objective on shares of Valneva in a research report on Tuesday, April 15th. Guggenheim dropped their price objective on Valneva from $17.00 to $15.00 and set a "buy" rating on the stock in a report on Monday, March 24th.

Valneva Price Performance

The company has a debt-to-equity ratio of 0.70, a current ratio of 2.78 and a quick ratio of 2.25. The firm has a market cap of $552.83 million, a price-to-earnings ratio of -50.85 and a beta of 1.85. The stock has a 50-day moving average price of $6.82 and a 200 day moving average price of $5.72.

Valneva (NASDAQ:VALN - Get Free Report) last issued its quarterly earnings data on Thursday, March 20th. The company reported ($0.54) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.32). The firm had revenue of $56.48 million during the quarter, compared to analysts' expectations of $55.64 million. Valneva had a negative net margin of 4.35% and a negative return on equity of 3.93%. As a group, equities research analysts forecast that Valneva SE will post 0.13 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of VALN. Wells Fargo & Company MN raised its stake in shares of Valneva by 14.3% during the 4th quarter. Wells Fargo & Company MN now owns 246,766 shares of the company's stock worth $1,079,000 after buying an additional 30,859 shares in the last quarter. ABC Arbitrage SA acquired a new stake in shares of Valneva during the 4th quarter valued at approximately $84,000. Finally, GAMMA Investing LLC purchased a new stake in shares of Valneva during the 1st quarter worth approximately $94,000. 11.39% of the stock is currently owned by hedge funds and other institutional investors.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.